The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations

Grants

Funding Acknowledgements

BL, RJ and LD are supported by National Health and Medical Research Council (NHMRC) research fellowships (#1073858, #1054674 and #1045318). PD is the recipient of an ARC Future Fellowship. The National Drug and Alcohol Research Centre at the University of NSW is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund. These studies would not have been possible without the generous participation of people who inject drugs and of people who receive treatment for opioid dependence. We thank the Suboxone (R) Post-marketing Surveillance Study Advisory Committee members (comprised of clinicians, policymakers, user group representatives and other researchers, none of whom were employees of Reckitt Benckiser) for their feedback on the research questions, methodology and analyses. Thank you to Laura Sims, David Hunt and Ivana Kihas for assisting with data collection for the post-marketing surveillance studies of BNX film. Special thanks go to Dr Stefanie Leung (SESLHD) for her assistance in developing the client transfer questions, and Laura Sims for her comments on an earlier version of this manuscript.